Last edition
News about "solid tumor treatment"
Daiichi Sankyo Begins Clinical Development of CD25-Targeted ADC DS1025
Daiichi Sankyo advances DS1025 into clinical development as a potential first-in-class CD25-targeted Antibody Drug Conjugate (ADC) for patients with advanced solid tumors.
Solid Tumor Treatment | 01/09/2026 | By News Bureau
Biosyngen Gets FDA Approval for BRG01 for Phase II Clinical Trial
Biosyngen has announced that the US Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical trial.
Solid Tumor Treatment | 13/08/2024 | By Aishwarya | 497
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy